Halia Therapeutics获得诺和诺德黄金门票以推进肥胖和炎症研究-动脉网

Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research

CISION 等信源发布 2025-03-11 19:59



可切换为仅中文







Fully Sponsored BioLabs Lab Space to Support Halia's Next Phase of Development

全力资助的生物实验室空间，支持Halia下一阶段的发展

LEHI, Utah

犹他州，勒希

，

March 11, 2025

2025年3月11日

/PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for chronic inflammation and obesity-related diseases, announced today that it has been awarded the Novo Nordisk Golden Ticket.

/PRNewswire/ -- Halia Therapeutics，一家致力于开发慢性炎症和肥胖相关疾病新型疗法的临床阶段生物制药公司，今日宣布荣获诺和诺德黄金门票。

The Novo Nordisk Golden Ticket – BioLabs European Award is granted to promising biotech companies working on transformational therapies in cardiometabolic and obesity-related diseases. This award covers one lab bench, one desk, and BioLabs membership for one year, with the option to apply the value toward private lab space, pending availability.

诺和诺德金票——BioLabs欧洲奖授予那些致力于研究心代谢和肥胖相关疾病变革性疗法的有前景的生物技术公司。该奖项包含一个实验室工作台、一个办公桌以及一年的BioLabs会员资格，并可选择在有空余的情况下将奖励价值用于私人实验室空间申请。

It also ensures priority admission to BioLabs Heidelberg or .

它还确保优先录取到海德堡生物实验室或。

Paris

巴黎

, allowing awardees to access state-of-the-art laboratory infrastructure, shared research facilities, and direct engagement with Novo Nordisk's scientific and business executives. The Golden Ticket also grants Halia access to Novo Nordisk's scientific and industry advisors' team, offering mentorship and networking opportunities to accelerate its research..

，允许获奖者使用最先进的实验室基础设施、共享的研究设施，并直接与诺和诺德的科学和商业高管互动。黄金门票还使Halia有机会接触诺和诺德的科学和行业顾问团队，提供指导和 networking 机会以加速其研究。

'Receiving the Novo Nordisk Golden Ticket is a significant milestone for Halia Therapeutics,' said

“获得诺和诺德黄金门票对哈利亚治疗公司来说是一个重要的里程碑，”

David J. Bearss

戴维·J·贝尔斯

, Ph.D., CEO of Halia Therapeutics. 'This award provides valuable resources to accelerate our research and validates our approach to tackling chronic inflammation and obesity-related diseases. With access to BioLabs' premier facilities and mentorship from Novo Nordisk, we are in a stronger position to advance HT-6184 toward clinical development.'.

博士，Halia Therapeutics首席执行官。 “该奖项为我们提供了宝贵的资源以加速我们的研究，并验证了我们应对慢性炎症和肥胖相关疾病的方法。通过BioLabs的一流设施以及诺和诺德的指导，我们更有能力推动HT-6184走向临床开发。”

Halia's HT-6184 is a first-in-class NEK7/NLRP3 inflammasome inhibitor designed to target metaflammation—the chronic, low-grade inflammation associated with obesity, metabolic dysfunction, and related diseases. Preclinical studies have demonstrated that HT-6184 enhances the effects of

Halia的HT-6184是一款首创的NEK7/NLRP3炎性体抑制剂，旨在靶向代谢性炎症——与肥胖、代谢功能障碍及相關疾病相关的慢性、低度炎症。临床前研究已证明，HT-6184增强了

GLP-1

receptor agonists, promoting weight loss while preserving lean mass and reducing inflammation. The company is preparing to initiate a Phase 2 clinical study in combination with Semaglutide in early 2025.

受体激动剂，促进体重减轻的同时保留瘦体重并减少炎症。该公司正准备在 2025 年初启动与司美格鲁肽联合使用的 2 期临床研究。

Receiving this award further strengthens Halia's position in the European biotech ecosystem and provides a critical pathway for global expansion and strategic partnerships.

获得该奖项进一步巩固了Halia在欧洲生物技术生态系统中的地位，并为其全球扩张和战略合作伙伴关系提供了关键途径。

About Halia Therapeutics

关于哈利亚治疗公司

Halia Therapeutics is a clinical-stage biopharmaceutical company based in

Halia Therapeutics是一家临床阶段的生物制药公司，总部位于

Lehi, Utah

犹他州李海市

, focused on developing treatments for chronic inflammatory disorders and neurodegenerative diseases. Its lead candidate, HT-6184, targets the NEK7/NLRP3 inflammasome pathway to modulate inflammation in obesity and metabolic disorders. Additionally, HT-4253, a LRRK2 inhibitor, is being evaluated for its potential in neuroinflammation-related diseases.

，专注于开发治疗慢性炎症性疾病和神经退行性疾病的药物。其主要候选药物HT-6184靶向NEK7/NLRP3炎性体通路，以调节肥胖和代谢紊乱中的炎症。此外，HT-4253是一种LRRK2抑制剂，正在评估其在神经炎症相关疾病中的潜力。

Halia's pipeline aims to address the root causes of inflammation-driven diseases with significant unmet medical needs, including obesity, Alzheimer's disease, and lower-risk myelodysplastic syndromes (LR-MDS)..

Halia的管道旨在解决由炎症驱动的疾病的根本原因，这些疾病存在显著未满足的医疗需求，包括肥胖症、阿尔茨海默病和较低风险的骨髓增生异常综合征（LR-MDS）。

For more information, visit

欲了解更多信息，请访问

www.haliatx.com

and follow us on

关注我们

LinkedIn and Twitter (X)

LinkedIn 和 Twitter (X)

。

Company Contact

公司联系人

Halia Therapeutics